| Old Articles: <Older 5541-5550 Newer> |
|---|
 |
The Motley Fool
April 6, 2009
Brian Orelli |
FDA to Search Engines: You Lose! FDA cracks down on pharma ads, but search engines are the real losers. The FDA wants the drugmakers to stop making claims in sponsored link advertisements.   |
The Motley Fool
April 6, 2009
Michael P. Cecil |
Investing in Pharma? Remember Rule No. 1 Health care reform is likely this year. How will that affect your pharma investments? |
The Motley Fool
April 4, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry. |
The Motley Fool
April 3, 2009
Brian Orelli |
Gilead: Helping Investors Cope With the Market Diversifying seems to be paying off for the drugmaker. |
The Motley Fool
April 3, 2009
Rich Smith |
BABY Cries When She's Hungry Natus Medical is starved for sales. |
The Motley Fool
April 3, 2009
Brian Orelli |
Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately. |
The Motley Fool
April 3, 2009
Brian Orelli |
Toning Down a Treatment Elan and Wyeth drop the highest dose of their Alzheimer's drug. |
The Motley Fool
April 2, 2009
Brian Orelli |
A Diabetic Compromise Bristol-Myers and AstraZeneca will have to test their drug after it goes on the market. |
BusinessWeek
March 26, 2009
Aili McConnon |
Gilead Sciences: High-Performing Pharmaceutical Gilead owes much of its success to making it easier for patients to comply with complex and uncomfortable drug regimens. |
The Motley Fool
April 1, 2009
Brian Orelli |
Conservative Celgene's Conundrum The drugmaker said it expected to make the low end of its previous guidance ranges for non-GAAP revenue and earnings per share for the year. It's not bad news, but it hurt the company nonetheless. |
| <Older 5541-5550 Newer> Return to current articles. |
